The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...
Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...
China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...
Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...
Currently, the only two Alzheimer’s medications approved for market by the U.S. Food and Drug Administration (FDA) are ...
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...
For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...
For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...
Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback